JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut–liver axis and lipid metabolism DOI Creative Commons
Wenying Qi, Xu Cao,

Yue Chen

et al.

Phytomedicine, Journal Year: 2025, Volume and Issue: 140, P. 156559 - 156559

Published: March 5, 2025

Metabolic-associated fatty liver disease (MAFLD) is a prevalent chronic condition globally, characterized by suboptimal treatment outcomes. Traditional therapies often fail to address the multifaceted pathogenesis of MAFLD, which involves lipid metabolism, inflammation, and gut-liver axis dysregulation. JiGuCao Capsule formula (JCF), patented Chinese medicine, has demonstrated clinical efficacy in treatment, indicating its potential as new therapeutic option for MAFLD. This study aimed investigate effects underlying mechanisms JCF treating particularly focusing on impact pathology, intestinal health, gut microbiota composition. A MAFLD mouse model was developed administering high-fat diet 5% fructose water 16 weeks. At week 8, mice exhibited significant steatosis, insulin resistance. Fifty were allocated into two groups: normal (ND) group with 19 feed (HFD) 31 mice. Seven from each sacrificed at 8 serological histopathological assessments. The remaining ND (n = 6), HFD + JCFL (human equivalent dose,780 mg/kg, n JCFH (threefold human dose, 2340 Polyene Phosphatidylcholine (PPC) dose,177.84 6) ND+ groups. Daily gavage started 9. 16, after fasting, body weight recorded, euthanized pentobarbital sodium. Mouse tissues feces collected histopathological, molecular biological, multi-omics analyses. effectively slowed progression decreasing hepatic accumulation inflammation. Treatment significantly reduced triglycerides inflammatory markers, including TNF-α IL-6. enhanced repaired barrier, lowered cytokines intestines, indicated serum LPS restored tight junction proteins expression, such claudin-1 occludin. Fecal analysis that elevated Lactobacillus levels Colidextribacter levels, correlating metabolic profiles. primary bioactive compounds identified responsible these betulinic acid, cholic deoxycholic oleanolic pectolinarigenin. Transcriptomic showed regulated key pathways involved pparγ-cd36 modulation ox-LDL levels. results indicate mitigates influencing metabolism. alleviates modulating Its involve improving barrier function, regulating microbiota, targeting axis. Active like acid support potential. shows promise novel further studies needed.

Language: Английский

Metabolic restoration: Rhubarb polysaccharides as a shield against non-alcoholic fatty liver disease DOI
Jiannan Qiu, Fangying Xu, Hangjie Wei

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: unknown, P. 141151 - 141151

Published: Feb. 1, 2025

Language: Английский

Citations

0
Preparation technologies, structural characteristics and biological activities of polysaccharides from bee pollen: A review DOI
Wangting Zhou,

Yuzhen He,

Jimin Lv

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 306, P. 141545 - 141545

Published: Feb. 26, 2025

Language: Английский

Citations

0
Recent insights and advances in gut microbiota's influence on host antiviral immunity DOI Creative Commons
Ying Liu,

Danying Yan,

Ran Chen

et al.

Frontiers in Microbiology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 27, 2025

A diverse array of microbial organisms colonizes the human body, collectively known as symbiotic communities. Among various pathogen infections that hosts encounter, viral represent one most significant public health challenges worldwide. The gut microbiota is considered an important biological barrier against and may serve a promising target for adjuvant antiviral therapy. However, potential impact on infection remains relatively understudied. In this review, we discuss specific regulatory mechanisms in immunity, highlighting recent advances how regulate host immune response, produce immune-related molecules, enhance host's defense viruses. Finally, also oral probiotics.

Language: Английский

Citations

0
Overview of the hazardous impacts of metabolism-disrupting chemicals on the progression of fatty liver diseases DOI Creative Commons

G.-H. An,

Jinyeop Song, Wei Ying

et al.

Molecular & Cellular Toxicology, Journal Year: 2025, Volume and Issue: 21(2), P. 387 - 397

Published: Feb. 27, 2025

Given the global increase in obesity, metabolic dysfunction-associated steatotic liver disease (MASLD) is a major health concern. Because primary organ for xenobiotic metabolism, impact of environmental stressors on homeostasis and MASLD has garnered significant interest over past few decades. The concept metabolism-disrupting chemicals (MDCs) been introduced to underscore importance factors homeostasis. Recent epidemiological biological studies suggest causal link between exposure MDCs prevalence progression MASLD. This review aims introduce emerging their representative toxic mechanisms. In particular, this focuses broadening understanding impacts or steatohepatitis (MASH) progression. research highlighted contaminants, such as heavy metals, microplastics, pesticides, have potential influence hepatic metabolism aggravate MASLD/MASH These not only directly affect lipid hepatocytes but also other cell types, immune cells stellate cells, well gut-liver axis. Collectively, these findings contribute establishing well-defined adverse outcome pathway identify novel therapeutic options diseases associated with pollutants.

Language: Английский

Citations

0
JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut–liver axis and lipid metabolism DOI Creative Commons
Wenying Qi, Xu Cao,

Yue Chen

et al.

Phytomedicine, Journal Year: 2025, Volume and Issue: 140, P. 156559 - 156559

Published: March 5, 2025

Metabolic-associated fatty liver disease (MAFLD) is a prevalent chronic condition globally, characterized by suboptimal treatment outcomes. Traditional therapies often fail to address the multifaceted pathogenesis of MAFLD, which involves lipid metabolism, inflammation, and gut-liver axis dysregulation. JiGuCao Capsule formula (JCF), patented Chinese medicine, has demonstrated clinical efficacy in treatment, indicating its potential as new therapeutic option for MAFLD. This study aimed investigate effects underlying mechanisms JCF treating particularly focusing on impact pathology, intestinal health, gut microbiota composition. A MAFLD mouse model was developed administering high-fat diet 5% fructose water 16 weeks. At week 8, mice exhibited significant steatosis, insulin resistance. Fifty were allocated into two groups: normal (ND) group with 19 feed (HFD) 31 mice. Seven from each sacrificed at 8 serological histopathological assessments. The remaining ND (n = 6), HFD + JCFL (human equivalent dose,780 mg/kg, n JCFH (threefold human dose, 2340 Polyene Phosphatidylcholine (PPC) dose,177.84 6) ND+ groups. Daily gavage started 9. 16, after fasting, body weight recorded, euthanized pentobarbital sodium. Mouse tissues feces collected histopathological, molecular biological, multi-omics analyses. effectively slowed progression decreasing hepatic accumulation inflammation. Treatment significantly reduced triglycerides inflammatory markers, including TNF-α IL-6. enhanced repaired barrier, lowered cytokines intestines, indicated serum LPS restored tight junction proteins expression, such claudin-1 occludin. Fecal analysis that elevated Lactobacillus levels Colidextribacter levels, correlating metabolic profiles. primary bioactive compounds identified responsible these betulinic acid, cholic deoxycholic oleanolic pectolinarigenin. Transcriptomic showed regulated key pathways involved pparγ-cd36 modulation ox-LDL levels. results indicate mitigates influencing metabolism. alleviates modulating Its involve improving barrier function, regulating microbiota, targeting axis. Active like acid support potential. shows promise novel further studies needed.

Language: Английский

Citations

0